{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:27Z","timestamp":1789140687988,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"DOI":"10.1186\/s40942-026-00860-z","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:07:02Z","timestamp":1776863222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world performance of faricimab for neovascular age-related macular degeneration and diabetic macular edema: experience from the BrazilRetNet multicenter study. Report 1"],"prefix":"10.1186","volume":"12","author":[{"given":"Vinicius","family":"Kniggendorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago C.","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor D. M.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo S.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio V.","family":"Regatieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata F.","family":"Sugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaldo","family":"Bordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna S.","family":"Nutels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Augusto","family":"Moreira-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Victor C.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio B.","family":"Nehemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco M.","family":"Damico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro C.","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lavinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleide G.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Eduardo D.","family":"Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francyne V.","family":"Cyrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wener","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz","family":"Roisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswaldo F.","family":"Brasil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel C.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando K.","family":"Malerbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando M.","family":"Penha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BrazilRetNet, Brazilian Retinal Research Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"6","key":"860_CR1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.5935\/0004-2749.20200082","volume":"83","author":"V Kniggendorf","year":"2020","unstructured":"Kniggendorf V, Dreyfuss JL, Regatieri CV. Age-related macular degeneration: a review of current therapies and new treatments. Arq Bras Oftalmol. 2020;83(6):552\u201361.","journal-title":"Arq Bras Oftalmol"},{"key":"860_CR2","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OPTH.S185052","volume":"12","author":"KL Spooner","year":"2018","unstructured":"Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient\u2019s perspective. Clin Ophthalmol. 2018;12:2483\u201391.","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"860_CR3","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292\u20139.","journal-title":"Ophthalmology"},{"issue":"9","key":"860_CR4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","volume":"127","author":"AR Glassman","year":"2020","unstructured":"Glassman AR, Wells JA 3rd, Josic K, Maguire MG, Antoszyk AN, Baker C, et al. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology. 2020;127(9):1201\u201310.","journal-title":"Ophthalmology"},{"issue":"8","key":"860_CR5","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40123-024-00980-5","volume":"13","author":"E Giancipoli","year":"2024","unstructured":"Giancipoli E, Guglielmi A, Bux AV, Clima GME, Pignatelli F, Boscia F, et al. Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME). Ophthalmol Ther. 2024;13(8):2163\u201384.","journal-title":"Ophthalmol Ther"},{"key":"860_CR6","doi-asserted-by":"crossref","unstructured":"Ferro Desideri L, Traverso CE, Nicolo M, Munk MR. Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics. 2023;15(5).","DOI":"10.3390\/pharmaceutics15051413"},{"issue":"2","key":"860_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","volume":"4","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A. SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States. Ophthalmol Retina. 2020;4(2):122\u201333.","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"860_CR8","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/eye.2017.81","volume":"31","author":"M Ashraf","year":"2017","unstructured":"Ashraf M, Souka AAR. Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. Eye (Lond). 2017;31(11):1523\u201336.","journal-title":"Eye (Lond)"},{"issue":"11","key":"860_CR9","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Lundh P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8(11):1265\u201388.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"860_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1161\/01.RES.87.7.603","volume":"87","author":"JR Gamble","year":"2000","unstructured":"Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res. 2000;87(7):603\u20137.","journal-title":"Circ Res"},{"issue":"9","key":"860_CR11","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1172\/JCI84871","volume":"126","author":"M Kim","year":"2016","unstructured":"Kim M, Allen B, Korhonen EA, Nitschke M, Yang HW, Baluk P, et al. Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. J Clin Invest. 2016;126(9):3511\u201325.","journal-title":"J Clin Invest"},{"issue":"6","key":"860_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1161\/01.RES.0000063422.38690.DC","volume":"92","author":"DP Hughes","year":"2003","unstructured":"Hughes DP, Marron MB, Brindle NP. The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2. Circ Res. 2003;92(6):630\u20136.","journal-title":"Circ Res"},{"issue":"12","key":"860_CR13","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/sj.eye.6702716","volume":"21","author":"YL Wang","year":"2007","unstructured":"Wang YL, Hui YN, Guo B, Ma JX. Strengthening tight junctions of retinal microvascular endothelial cells by pericytes under normoxia and hypoxia involving angiopoietin-1 signal way. Eye (Lond). 2007;21(12):1501\u201310.","journal-title":"Eye (Lond)"},{"issue":"4","key":"860_CR14","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.2337\/diabetes.53.4.1104","volume":"53","author":"HP Hammes","year":"2004","unstructured":"Hammes HP, Lin J, Wagner P, Feng Y, Vom Hagen F, Krzizok T, et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes. 2004;53(4):1104\u201310.","journal-title":"Diabetes"},{"key":"860_CR15","doi-asserted-by":"crossref","unstructured":"Li P, Fan H. Pericyte loss in diseases. Cells. 2023;12(15).","DOI":"10.3390\/cells12151931"},{"issue":"5","key":"860_CR16","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","volume":"263","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Mar F, Amador MJ, Chang A, Gibson K, Joussen AM, et al. Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Graefes Arch Clin Exp Ophthalmol. 2025;263(5):1239\u201347.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"860_CR17","first-page":"10","volume":"5","author":"M Buyse","year":"2016","unstructured":"Buyse M. Phase III design: principles. Chin Clin Oncol. 2016;5(1):10.","journal-title":"Chin Clin Oncol"},{"issue":"6","key":"860_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024;131(6):708\u201323.","journal-title":"Ophthalmology"},{"issue":"6","key":"860_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.oret.2024.11.015","volume":"9","author":"RA Goldberg","year":"2025","unstructured":"Goldberg RA, Mar FA, Csaky K, Amador M, Khanani AM, Gibson K, et al. Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE\/RHINE. Ophthalmol Retina. 2025;9(6):515\u201326.","journal-title":"Ophthalmol Retina"},{"key":"860_CR20","doi-asserted-by":"crossref","unstructured":"Sheth VS, Schlottmann P, Lai TYY, Abreu F, Chang A, Eter N, et al. Four-year outcomes of faricimab in diabetic macular edema: results from the RHONE-X extension Trial. Ophthalmology. 2026.","DOI":"10.1016\/j.ophtha.2026.01.001"},{"key":"860_CR21","unstructured":"Khanani AM. Four-year outcomes of faricimab in diabetic macular edema: results from the RHONE-X extension study. Macula Soc Meet. 2025;12\u201315."},{"issue":"8","key":"860_CR22","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. Tenaya and lucerne: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"key":"860_CR23","unstructured":"Khanani AM. Four-Year Outcomes of Faricimab in nAMD: Safety and efficacy results from the AVONELLE-X long-term extension trial. 25th EURETINA Congress; 04\u201307 September 2025; Paris, France 2025."},{"key":"860_CR24","doi-asserted-by":"publisher","first-page":"12302","DOI":"10.3389\/jpps.2024.12302","volume":"27","author":"K Zisis","year":"2024","unstructured":"Zisis K, Pavi E, Geitona M, Athanasakis K. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process. J Pharm Pharm Sci. 2024;27:12302.","journal-title":"J Pharm Pharm Sci"},{"issue":"4","key":"860_CR25","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.xops.2025.100744","volume":"5","author":"V Chaudhary","year":"2025","unstructured":"Chaudhary V, Guymer R, Artignan A, Downey A, Singh RP. Real-World Evidence for Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Scoping Review. Ophthalmol Sci. 2025;5(4):100744.","journal-title":"Ophthalmol Sci"},{"issue":"6748","key":"860_CR26","doi-asserted-by":"publisher","first-page":"eadl3564","DOI":"10.1126\/science.adl3564","volume":"388","author":"K Nunes","year":"2025","unstructured":"Nunes K, Araujo Castro ESM, Rodrigues MR, Lemes RB, Pezo-Valderrama P, Kimura L, et al. Admixture\u2019s impact on Brazilian population evolution and health. Science. 2025;388(6748):eadl3564.","journal-title":"Science"},{"issue":"28","key":"860_CR27","doi-asserted-by":"publisher","first-page":"8696","DOI":"10.1073\/pnas.1504447112","volume":"112","author":"FS Kehdy","year":"2015","unstructured":"Kehdy FS, Gouveia MH, Machado M, Magalhaes WC, Horimoto AR, Horta BL, et al. Origin and dynamics of admixture in Brazilians and its effect on the pattern of deleterious mutations. Proc Natl Acad Sci U S A. 2015;112(28):8696\u2013701.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"860_CR28","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046\u201350.","journal-title":"Retina"},{"issue":"17","key":"860_CR29","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u2009\u2013\u20096 month results. Eye (Lond). 2023;37(17):3574\u201381.","journal-title":"Eye (Lond)"},{"issue":"7","key":"860_CR30","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41433-023-02900-6","volume":"38","author":"A Gigon","year":"2024","unstructured":"Gigon A, Iskandar A, Kasser S, Naso S, Zola M, Mantel I. Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration. Eye (Lond). 2024;38(7):1342\u20138.","journal-title":"Eye (Lond)"},{"issue":"8","key":"860_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3928\/23258160-20250304-02","volume":"56","author":"FS Ali","year":"2025","unstructured":"Ali FS, Tabano DC, Borkar DS, Leng T, Garmo V, Ahmed A, et al. Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina. 2025;56(8):468\u201377.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"18","key":"860_CR32","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1038\/s41433-025-04059-8","volume":"39","author":"T Peto","year":"2025","unstructured":"Peto T, Pearce I, Talks J, de Salvo G, Patel PJ, de Silva SR, et al. Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study. Eye (Lond). 2025;39(18):3350\u20138.","journal-title":"Eye (Lond)"},{"issue":"1","key":"860_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, Thomas M, Fong RD, Smith K, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitreous. 2024;10(1):5.","journal-title":"Int J Retina Vitreous"},{"issue":"8","key":"860_CR34","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3928\/23258160-20250304-01","volume":"56","author":"DS Borkar","year":"2025","unstructured":"Borkar DS, Tabano DC, Ali FS, Leng T, Garmo V, Ahmed A, et al. Early Outcomes After Initiation of Faricimab in Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2025;56(8):478\u201386.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00860-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00860-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00860-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:34:07Z","timestamp":1781649247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00860-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["860"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00860-z","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review boards of the participating centers (CAAE 79630824.1.0000.5370), and the study adhered to the tenets of the Declaration of Helsinki. All participants provided written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}